Neuroinflammation

#Neuroinflammation #Neuroscience #University of Cambridge

Collaboration set to develop neuroinflammation therapeutics 

Neuroscience company AndzonBio2 has announced it will collaborate with the University of Cambridge and Cambridge Enterprise to develop therapeutics for neuroinflammation.  The agreement states the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities. This will also include the drug discovery platform developed… Read More

#News

Neurons in Parkinson's disease
#Neuroinflammation #Neuroscience #NodThera #Parkinson's #Phase II trial

Oral NLRP3 inhibitor reverses neuroinflammation in Parkinson’s

NodThera has shared positive data from its Parkinson’s disease Phase Ib/IIa study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3 inflammasome inhibitor.  In the first publication to demonstrate the clinical potential of an oral, fully brain-penetrant NLRP3 inhibitor in Parkinson’s disease, NT-0796 was shown to be… Read More

#News

Neuroscience
#Collaboration #JAK inhibitor #Neuroinflammation #Parkinson's #Receptor.AI #Sareum Holdings

Sareum and ReceptorAI collaborate on TYK2/JAK1 inhibitors

Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors.  The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s disease.   Sareum’s previously… Read More

#Business & Investment #News

Brain inflammation
#Neuroinflammation #Neuroscience #Preclinical development #ReAlta

Pegtarazimod reduces brain inflammation, says new study data

A new study has shown that pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischaemic encephalopathy (HIE), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.  The article in the American Journal of Perinatology highlights that pegtarazimod reduces… Read More

#News

Researcher loads DNA samples for PCR analysis
#Acute inflammatory conditions #Domain Therapeutics #GPCRs #Neuroinflammation

PAR2-targeting drug has “game-changing potential”

Domain Therapeutics has announced plans to progress DT-9046, a candidate it says has game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine.  PAR2 has emerged as a pivotal therapeutic in inflammatory diseases due to its… Read More

#News

Treg cells
#Cell therapy #Mouse models #Neuroinflammation #PolTREG #Preclinical investigations

Preclinical study to assess CAR-Treg cells for neuroinflammation

PolTREG has launched a preclinical study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. The study will measure the safety and efficacy of the therapy and data is anticipated by March 2025. PolTREG’s CAR-Treg cells are manufactured using the same technology… Read More

#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovative advances in neuroscience: Secure your place

It’s less than one week now till our exclusive online event ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. Register now to secure your place on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News

Neurons
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovation in neuroscience: Hear from the experts

Register now to hear from neuroscience industry experts at ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. The online event will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News

Neurons
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Discover the latest advances in neuroscience

Register now to join this unique online event. Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. You will hear from Fiona… Read More

Webinar date:
#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

New online event: Innovative advances in neuroscience

Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Join this free webinar to learn about innovation taking place… Read More

Webinar date:
#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovative advances in neuroscience

In this webinar, hosted by DDW and sponsored by ACROBiosystems, you will learn about the innovative advances in neuroscience. You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at… Read More

Webinar date:
Sponsored by ACROBiosystems
#Webinars

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week reflects the high level of interest and investment in… Read More

#News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

This week in drug discovery (21-25 August)  

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #epilepsy #Neuroinflammation #Parkinson's #Phase I trial #Ventus Therapeutics

NLRP3 inhibitor for neuroinflammation enters trials

The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient. Based on the safety margins demonstrated in IND-enabling studies, the Phase I trial is designed to fully explore VENT-02’s pharmacodynamics, safety, and… Read More

#News

Idiopathic intracranial hypertension
#Brain #Neuroinflammation #Neurology #Phase II trial #Type 2 diabetes #University of Birmingham

Type 2 diabetes drug could treat blinding IIH headaches

Patients with ‘blinding’ headaches known as idiopathic intracranial hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study was led by a team of neurologists from the University of Birmingham and University Hospitals Birmingham, and… Read More

#News #Trending News

MRI of the brain
#epilepsy #Mouse models #Neuroinflammation #Neuroscience

Neuroscientists discover new drug candidate for treating epilepsy

Neuroscientists have identified and developed a new drug candidate that has the potential to effectively treat temporal lobe epilepsy (TLE) by suppressing neuroinflammation.  Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. Most of these… Read More

#News #Trending News